Reuters logo
BRIEF-Orexo says EMA issues positive opinion for opioid dependence treatment with Zubsolv
September 15, 2017 / 11:50 AM / a month ago

BRIEF-Orexo says EMA issues positive opinion for opioid dependence treatment with Zubsolv

Sept 15 (Reuters) - Orexo

* CHMP positive opinion for opioid dependence treatment with Zubsolv® (buprenorphine and naloxone) in Europe

* Mundipharma and Orexo today announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for Zubsolv (buprenorphine and naloxone sublingual tablet) for use in the treatment of opioid dependence

* Says European Commission will now review CHMP opinion and a final decision is expected in q4, 2017 Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below